Wegovy vs Mounjaro in South Africa (2026): The Definitive Weight Loss Comparison

If your doctor has mentioned Wegovy or Mounjaro for weight management, you are looking at the two most effective prescription weight loss injections available globally. Both are weekly injections that work on gut hormones to reduce appetite and help you lose significant weight -- but they are not the same drug.

This comparison breaks down everything a South African patient needs to know: how they work, clinical trial results, side effects, cost in Rands, and which one you can actually get from your local pharmacy.

Quick Comparison: Wegovy vs Mounjaro at a Glance

How They Work: Single vs Dual Hormone Action

Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1 (glucagon-like peptide-1), which signals your brain to feel full, slows stomach emptying, and reduces food cravings. Think of it as turning up the volume on the "I'm satisfied" signal your body already produces after eating.

Mounjaro (tirzepatide) works on two gut hormones simultaneously -- both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is why researchers call it a "twincretin." The GIP component adds extra metabolic benefits: it improves how your body processes fat, enhances insulin sensitivity, and may contribute to the additional weight loss seen in clinical trials.

Clinical Trial Results: STEP vs SURMOUNT

Both drugs have been tested in large, rigorous clinical trials. Here is how their headline results compare:

What do these numbers mean in real terms?

For a South African woman weighing 100kg:

• On Wegovy: expected loss of roughly 15kg over 16 months (down to ~85kg)
• On Mounjaro (15mg): expected loss of roughly 22kg over 18 months (down to ~78kg)

That 7kg difference is clinically meaningful -- it can be the difference between needing blood pressure medication or not. However, these are averages. Some patients respond better to semaglutide, and individual results depend heavily on diet, exercise, and genetics.

Side Effects Comparison

Both medications share a similar gastrointestinal side effect profile, which is most noticeable during the dose escalation period (the first 3-4 months):

Key takeaway: Mounjaro tends to cause fewer GI side effects than Wegovy at comparable or even greater levels of weight loss. This is a significant advantage for patients who struggled with nausea on semaglutide. Researchers believe the dual GLP-1/GIP mechanism may distribute the metabolic load more evenly, resulting in better tolerability.

Both drugs carry rare but serious warnings for pancreatitis, gallbladder problems, and a theoretical risk of thyroid C-cell tumours (based on rodent studies). If you have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, neither medication is appropriate.

Cost in South Africa (2026)

Let's talk Rands. Weight loss medications are a significant monthly expense in South Africa:

Wegovy is the more affordable and accessible option for most South Africans. It is stocked at major pharmacy chains and has some medical aid coverage pathways, especially on comprehensive plans. Mounjaro requires more effort to source and is rarely covered by medical aid schemes as of mid-2026.

Availability and SAHPRA Status

Wegovy in South Africa

Wegovy has received SAHPRA (South African Health Products Regulatory Authority) approval specifically for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. You can walk into Dis-Chem or Clicks with a script and collect it -- stock permitting. Supply shortages do occur, so ask your pharmacist to notify you when stock arrives.

Mounjaro in South Africa

Mounjaro (tirzepatide) is registered by SAHPRA for type 2 diabetes under the Mounjaro brand name but is not yet registered for weight management. To use it specifically for weight loss, your doctor must apply for a Section 21 exemption through SAHPRA -- an individual patient access pathway that takes 2-6 weeks for approval.

Eli Lilly's dedicated weight loss version, Zepbound (same tirzepatide molecule, marketed for obesity), is approved in the US and EU but has not yet received SAHPRA registration in South Africa.

Who Should Choose Which?

Wegovy might be right for you if:

• You want a SAHPRA-approved weight loss medication with a clear regulatory pathway
• Your medical aid covers semaglutide for weight management
• You prefer the convenience of buying from Dis-Chem or Clicks
• You are starting your first GLP-1 medication and want the most-studied option
• You have responded well to Ozempic and want the higher weight-loss dose

Mounjaro might be right for you if:

• You have hit a weight loss plateau on semaglutide (Wegovy/Ozempic)
• You experienced significant nausea on Wegovy and want potentially better tolerability
• You have type 2 diabetes alongside obesity (Mounjaro is registered for diabetes)
• You need maximum weight loss and are willing to navigate Section 21 access
• Your budget can accommodate the higher cost and potentially limited medical aid coverage

Switching from Wegovy to Mounjaro

If you have been on Wegovy for 6+ months and your weight loss has stalled, switching to Mounjaro is an increasingly common strategy. Here is what the process looks like in South Africa:

1. Discuss with your doctor -- they need to assess whether a plateau is truly medication-related or linked to diet, exercise, or other factors
2. Section 21 application -- your doctor submits an application to SAHPRA for tirzepatide access, which typically takes 2-6 weeks
3. Dose transition -- you would finish your current Wegovy pen, then start Mounjaro at the lowest dose (2.5mg weekly) and titrate up over 4-5 months
4. Monitor closely -- expect a new round of GI side effects during the transition, though potentially milder than your initial Wegovy experience

Read our detailed guide on managing weight after stopping GLP-1 medications if you are considering any changes to your treatment plan.

What About the Next Generation?

The weight loss injection landscape is evolving rapidly. Several next-generation drugs are in development that may eventually outperform both Wegovy and Mounjaro:

• Retatrutide -- Eli Lilly's triple-action (GLP-1/GIP/glucagon) injectable showed ~24% weight loss in phase 2 trials
• CagriSema -- Novo Nordisk's combination of semaglutide + cagrilintide achieved ~22% weight loss
• Survodutide -- Boehringer Ingelheim's dual GLP-1/glucagon agonist with strong liver fat reduction
• Amycretin -- Novo Nordisk's oral pill combining GLP-1 + amylin activity, potentially ending the need for injections
• Orforglipron -- Eli Lilly's oral GLP-1 tablet, aiming for injection-level results in pill form

These are still in clinical trials and are unlikely to reach South African pharmacies before 2027-2028 at the earliest. For now, Wegovy and Mounjaro remain the gold standard.

Our Verdict: Wegovy for Most South Africans, Mounjaro When You Need More

For the majority of South African patients starting prescription weight loss treatment in 2026, Wegovy is the practical first choice. It is SAHPRA-approved for weight loss, available at mainstream pharmacies, more likely to be covered by medical aid, and delivers clinically meaningful results of ~15% body weight loss.

Mounjaro is the step-up option for patients who need maximum efficacy, have plateaued on semaglutide, or who have type 2 diabetes alongside obesity. Its dual hormone mechanism delivers superior weight loss with potentially fewer GI side effects -- but the access barriers and higher cost make it a second-line choice for most.

Further Reading

• Wegovy in South Africa: Full Guide
• Mounjaro (Tirzepatide) South Africa Guide
• Ozempic South Africa: Cost, Availability, Results
• Semaglutide Side Effects: What to Expect
• All Weight Loss Injections Available in SA
• Best Exercises While on Semaglutide
• High Protein Diet for Weight Loss
• Ozempic Cost Breakdown in South Africa
• Next-Generation GLP-1 Drugs Coming to SA